Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the populat...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43530 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-43530 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-435302018-04-25T07:36:43Z Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho Biochemistry, Genetics and Molecular Biology Agricultural and Biological Sciences Arts and Humanities © 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A > G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients. 2018-01-24T03:49:46Z 2018-01-24T03:49:46Z 2017-11-01 Journal 17448042 14622416 2-s2.0-85034419484 10.2217/pgs-2017-0128 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43530 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Biochemistry, Genetics and Molecular Biology Agricultural and Biological Sciences Arts and Humanities |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Agricultural and Biological Sciences Arts and Humanities Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
description |
© 2017 Future Medicine Ltd. Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A nonlinear mixed effects model was used to develop the population pharmacokinetic model and investigate the influence of these polymorphisms and other patient specific covariates on the pharmacokinetics of tenofovir. Results: The estimated glomerular filtration rate calculated by the Cockcroft and Gault equation, concomitant use of lopinavir/ritonavir and ABCC4 3463A > G polymorphism were associated with tenofovir apparent oral clearance (CL/F). The use of lopinavir/ritonavir decreased tenofovir CL/F by 25%. Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA. Conclusion: Renal function, co-medication and genetic variation impact the pharmacokinetics of tenofovir. These factors should be taken into consideration to guide the individual tenofovir disoproxil fumarate dosage regimen in Thai HIV-infected patients. |
format |
Journal |
author |
Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho |
author_facet |
Kanokrat Rungtivasuwan Anchalee Avihingsanon Narukjaporn Thammajaruk Siwaporn Mitruk David M. Burger Kiat Ruxrungtham Chonlaphat Sukasem Baralee Punyawudho |
author_sort |
Kanokrat Rungtivasuwan |
title |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_short |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_full |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_fullStr |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_full_unstemmed |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients |
title_sort |
pharmacogenetics-based population pharmacokinetic analysis of tenofovir in thai hiv-infected patients |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85034419484&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43530 |
_version_ |
1681422390365519872 |